Rahul Khara Biography and Net Worth

Insider of Disc Medicine

Dr. Khara joins Disc Medicine from Acceleron where he served as Vice President, Legal and Chief Compliance Officer. In this role, he led the commercial legal and compliance functions. While at Acceleron, Dr. Khara led or supported a wide range of legal matters including facilitating the launch of Reblozyl® (luspatercept-aamt), Acceleron’s first commercial product, building the company’s commercial compliance program, and the successful acquisition of the company by Merck. Prior to Acceleron, Dr. Khara worked at the law firms of Arnold & Porter LLP and Sidley Austin LLP, where he helped biopharma companies in various stages of development navigate legal issues related to the clinical development of new assets, launch of new drug products, business development transactions, compliance, and enforcement. Dr. Khara received a Pharm.D. from the Ernest Mario School of Pharmacy at Rutgers University and a J.D. from the University of Michigan Law School.

What is Rahul Khara's net worth?: The estimated net worth of Rahul Khara is at least $756,907.55 as of February 3rd, 2025. Khara owns 14,035 shares of Disc Medicine stock worth more than $756,908 as of March 13th. This net worth estimate does not reflect any other assets that Khara may own. Learn More about Rahul Khara's net worth.
How old is Rahul Khara?: Khara is currently 42 years old. There are 7 older executives and no younger executives at Disc Medicine. The oldest executive at Disc Medicine is Dr. Donald William Nicholson Ph.D., Executive Chairman, who is 66 years old. Learn More on Rahul Khara's age.
How do I contact Rahul Khara?: The corporate mailing address for Khara and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Rahul Khara's contact information.
Has Rahul Khara been buying or selling shares of Disc Medicine?: Within the last three months, Rahul Khara has sold $887,175.00 in shares of Disc Medicine stock. Most recently, Rahul Khara sold 7,500 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $55.54, for a transaction totalling $416,550.00. Following the completion of the sale, the insider now directly owns 14,035 shares of the company's stock, valued at $779,503.90. Learn More on Rahul Khara's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 19 times. They sold a total of 395,005 shares worth more than $22,156,241.87. The most recent insider tranaction occured on March, 12th when Director Mona Ashiya sold 83,182 shares worth more than $4,529,259.90. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/12/2025.

Rahul Khara Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/3/2025	Sell	7,500	$55.54	$416,550.00	14,035
1/2/2025	Sell	7,500	$62.75	$470,625.00	14,035
11/22/2023	Sell	10,000	$51.73	$517,300.00
11/14/2023	Sell	4,900	$50.61	$247,989.00
11/3/2023	Sell	100	$50.00	$5,000.00

Rahul Khara Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $53.17

$52.59

$54.84

50 Day Range

MA: $56.62

$53.37

$63.82

2 Week Range

Now: $53.17

$25.60

$68.86

Volume

145,560 shs

Average Volume

360,333 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Rahul Khara Biography and Net Worth

What is Rahul Khara's net worth?

How old is Rahul Khara?

How do I contact Rahul Khara?

Has Rahul Khara been buying or selling shares of Disc Medicine?

Who are Disc Medicine's active insiders?

Are insiders buying or selling shares of Disc Medicine?